Allovir, Inc., a clinical-stage cell therapy company, is dedicated to the research and development of ready-to-use, multi-virus-specific allogeneic T-cell therapies (TSVs) to prevent and treat devastating virus-associated diseases. The company is headquartered in Cambridge, Massachusetts.